CTXR Stock Summary and Trading Ideas (Citius Pharmaceuticals | NASDAQ:CTXR)

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.

Citius Pharmaceuticals trades on the NASDAQ stock market under the symbol CTXR.

As of January 31, 2025, CTXR stock price declined to $2.71 with 31,195 million shares trading.

CTXR has a beta of 1.00, meaning it tends to be less sensitive to market movements. CTXR has a correlation of 0.01 to the broad based SPY ETF.

CTXR has a market cap of $23.29 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, CTXR traded as high as $50.25 and as low as $2.44.

The top ETF exchange traded funds that CTXR belongs to (by Net Assets): VTI, VXF.

CTXR has underperformed the market in the last year with a price return of -82.7% while the SPY ETF gained +25.5%. CTXR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -73.2% and -16.9%, respectively, while the SPY returned +5.3% and +2.9%, respectively.

CTXR support price is $2.61 and resistance is $3.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CTXR shares will trade within this expected range on the day.